This article comprehensively reviews current trends in T2DM treatment, the molecular profile of GLP-1, biological characteristics of GLP-1-secreting L-cells, the development of GLP-1-related pharmaceuticals, and advances in metabolic surgery (MS)
Clinical trials have consistently shown that Ozempic and Wegovy can lead to significant reductions in body weight, a crucial factor in the management of type 2 diabetes, as obesity is a major risk factor for the development of the disease
In clinical trials, liraglutide showed a placebo-corrected weight loss of around 5%, semaglutide 12%, and tirzepatide 18% [23]
2 College of Medicine, Chang Gung University, Taoyuan, Taiwan
Carvalho CM, Chew EH, Hashemy SI, Lu J, Holmgren A (2008) Inhibition of the human thioredoxin system